Search

Your search keyword '"Gross, W.L."' showing total 216 results
Start Over Author "Gross, W.L."
216 results on '"Gross, W.L."'

57. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis

Author

Wibisono, D., Csernok, E., Lamprecht, P., Holle, J.U., Gross, W.L., and Moosig, F.

Subjects
Wegener's granulomatosis -- Development and progression, Wegener's granulomatosis -- Research, Autoantibodies -- Physiological aspects, Autoantibodies -- Research, Chromosomal proteins -- Physiological aspects, Chromosomal proteins -- Genetic aspects, Chromosomal proteins -- Research, Vasculitis -- Research, Health
Published
2010

59. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans

Author

Liu, Kui, Li, Quan-Zhen, Delgado-Vega, Angelica M., Abelson, Anna-Karin, Sánchez, Elena, Kelly, Jennifer A., Li, Li, Liu, Yang, Zhou, Jinchun, Yan, Mei, Ye, Qiu, Liu, Shenxi, Xie, Chun, Zhou, Xin J., Chung, Sharon A., Pons-Estel, Bernardo, Witte, Torsten, de Ramón, Enrique, Bae, Sang-Cheol, Barizzone, Nadia, Sebastiani, Gian Domenico, Merrill, Joan T., Gregersen, Peter K., Gilkeson, Gary G., Kimberly, Robert P., Vyse, Timothy J., Kim, Il, D'Alfonso, Sandra, Martin, Javier, Harley, John B., Criswell, Lindsey A., Wakeland, Edward K., Alarcón-Riquelme, Marta E., Mohan, Chandra, Danieli, M.G., Galeazzi, M., Querini, P.R., Migliaresi, S., Scherbarth, H.R., Lopez, J.A., Motta, E.L., Gamron, S., Drenkard, C., Menso, E., Allievi, A., Tate, G.A., Presas, J.L., Palatnik, S.A., Abdala, M., Bearzotti, M., Alvarellos, A., Caeiro, F., Bertoli, A., Paira, S., Roverano, S., Graf, C.E., Bertero, E., Caprarulo, C., Buchanan, G., Guillerón, C., Grimaudo, S., Manni, J., Catoggio, L.J., Soriano, E.R., Santos, C.D., Prigione, C., Ramos, F.A., Navarro, S.M., Berbotto, G.A., Jorfen, M., Romero, E.J., Garcia, M.A., Marcos, J.C., Marcos, A.I., Perandones, C.E., Eimon, A., Battagliotti, C.G., Armadi-Simab, K., Gross, W.L., Gromica-Ihle, E., Peter, H.H., Manger, K., Schnarr, S., Zeidler, H., Schmidt, R.E., Ortego, N., Callejas, J.L., Jiménez-Alonso, J., Sabio, M., Sánchez-Román, J., Garcia-Hernandez, F.J., Camps, M., López-Nevot, M.A., González-Escribano, M.F., Harley, J.H., Riquelme, M.A., Kimberly, R., Criswell, L., Langefeld, C., Tsao, B., Jacob, C., Liu, Kui, Li, Quan-Zhen, Delgado-Vega, Angelica M., Abelson, Anna-Karin, Sánchez, Elena, Kelly, Jennifer A., Li, Li, Liu, Yang, Zhou, Jinchun, Yan, Mei, Ye, Qiu, Liu, Shenxi, Xie, Chun, Zhou, Xin J., Chung, Sharon A., Pons-Estel, Bernardo, Witte, Torsten, de Ramón, Enrique, Bae, Sang-Cheol, Barizzone, Nadia, Sebastiani, Gian Domenico, Merrill, Joan T., Gregersen, Peter K., Gilkeson, Gary G., Kimberly, Robert P., Vyse, Timothy J., Kim, Il, D'Alfonso, Sandra, Martin, Javier, Harley, John B., Criswell, Lindsey A., Wakeland, Edward K., Alarcón-Riquelme, Marta E., Mohan, Chandra, Danieli, M.G., Galeazzi, M., Querini, P.R., Migliaresi, S., Scherbarth, H.R., Lopez, J.A., Motta, E.L., Gamron, S., Drenkard, C., Menso, E., Allievi, A., Tate, G.A., Presas, J.L., Palatnik, S.A., Abdala, M., Bearzotti, M., Alvarellos, A., Caeiro, F., Bertoli, A., Paira, S., Roverano, S., Graf, C.E., Bertero, E., Caprarulo, C., Buchanan, G., Guillerón, C., Grimaudo, S., Manni, J., Catoggio, L.J., Soriano, E.R., Santos, C.D., Prigione, C., Ramos, F.A., Navarro, S.M., Berbotto, G.A., Jorfen, M., Romero, E.J., Garcia, M.A., Marcos, J.C., Marcos, A.I., Perandones, C.E., Eimon, A., Battagliotti, C.G., Armadi-Simab, K., Gross, W.L., Gromica-Ihle, E., Peter, H.H., Manger, K., Schnarr, S., Zeidler, H., Schmidt, R.E., Ortego, N., Callejas, J.L., Jiménez-Alonso, J., Sabio, M., Sánchez-Román, J., Garcia-Hernandez, F.J., Camps, M., López-Nevot, M.A., González-Escribano, M.F., Harley, J.H., Riquelme, M.A., Kimberly, R., Criswell, L., Langefeld, C., Tsao, B., and Jacob, C.

Abstract

Immune-mediated nephritis contributes to disease in systemic lupus erythematosus, Goodpasture syndrome (caused by antibodies specific for glomerular basement membrane [anti-GBM antibodies]), and spontaneous lupus nephritis. Inbred mouse strains differ in susceptibility to anti-GBM antibody-induced and spontaneous lupus nephritis. This study sought to clarify the genetic and molecular factors that maybe responsible for enhanced immune-mediated renal disease in these models. When the kidneys of 3 mouse strains sensitive to anti-GBM antibody-induced nephritis were compared with those of 2 control strains using microarray analysis, one-fifth of the underexpressed genes belonged to the kallikrein gene family,which encodes serine esterases. Mouse strains that upregulated renal and urinary kallikreins exhibited less evidence of disease. Antagonizing the kallikrein pathway augmented disease, while agonists dampened the severity of anti-GBM antibody-induced nephritis. In addition, nephritis-sensitive mouse strains had kallikrein haplotypes that were distinct from those of control strains, including several regulatory polymorphisms,some of which were associated with functional consequences. Indeed, increased susceptibility to anti-GBM antibody-induced nephritis and spontaneous lupus nephritis was achieved by breeding mice with a genetic interval harboring the kallikrein genes onto a disease-resistant background. Finally, both human SLE and spontaneous lupus nephritis were found to be associated with kallikrein genes, particularly KLK1 and the KLK3 promoter, when DNA SNPs from independent cohorts of SLE patients and controls were compared. Collectively, these studies suggest that kallikreins are protective disease-associated genes in anti-GBM antibody-induced nephritis and lupus.

Published
2009
Full Text
View/download PDF

62. Pachymeningitis in mixed connective tissue disease

Author

Ahmadi-Simab, K., Lamprecht, P., Reuter, M., and Gross, W.L.

Subjects
Meningitis -- Case studies, Meningitis -- Diagnosis, Dura mater -- Diseases, Connective tissue diseases -- Case studies, Connective tissue diseases -- Diagnosis, Hydrocephalus -- Diagnosis, Hydrocephalus -- Care and treatment, Health
Published
2005

70. European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials EUROPEAN COMMUNITY STUDY GROUP ON CLINICAL TRIALS IN SYSTEMIC VASCULITIS ECSYSVASTRIAL (BMHl-Cr93-1078)

Author

Rasmussen, N. Jayne, D.R.W. Abramowicz, D. Andrassy, K. Bacon, P.A. Cohen Tervaert, J.W. Dadonlené, J. Feighery, C. Van Es, L.A. Ferrario, F. Gaskin, G. Gregorini, G. De Groot, K. Gross, W.L. Grönhagen-Riska, C. Guillevin, L. Hagen, E.C. Heigl, Z. Hermans, J. Kallenberg, C.G.M. Landais, P. Lesavre, P. Lockwood, C.M. Luqmani, R. Mirapeix, E. Pettersson, E. Pusey, C. Savage, C.O.S. Sinico, R.A. Specks, U. Tzioufas, A.G. Westman, K.W.A. Wiik, A. Van Der Woude, F.

Published
1995

75. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement

Author

Hunzelmann, N., primary, Genth, E., additional, Krieg, T., additional, Lehmacher, W., additional, Melchers, I., additional, Meurer, M., additional, Moinzadeh, P., additional, Muller-Ladner, U., additional, Pfeiffer, C., additional, Riemekasten, G., additional, Schulze-Lohoff, E., additional, Sunderkoetter, C., additional, Weber, M., additional, Worm, M., additional, Klaus, P., additional, Rubbert, A., additional, Steinbrink, K., additional, Grundt, B., additional, Hein, R., additional, Scharffetter-Kochanek, K., additional, Hinrichs, R., additional, Walker, K., additional, Szeimies, R.-M., additional, Karrer, S., additional, Muller, A., additional, Seitz, C., additional, Schmidt, E., additional, Lehmann, P., additional, Foeldvari, I., additional, Reichenberger, F., additional, Gross, W.L., additional, Kuhn, A., additional, Haust, M., additional, Reich, K., additional, Bohm, M., additional, Saar, P., additional, Fierlbeck, G., additional, Kotter, I., additional, Lorenz, H.-M., additional, Blank, N., additional, Grafenstein, K., additional, Juche, A., additional, Aberer, E., additional, Bali, G., additional, Fiehn, C., additional, Stadler, R., additional, and Bartels, V., additional

Published
2008
Full Text
View/download PDF

81. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays

Author

Hagen, Ernst Christiaan, Andrassy, Konrad, Csernok, Elena, Daha, Mohamed, Gaskin, Gill, Gross, W.L., Hansen, Bettina, Heigl, Z., Hermans, Julie, Jayne, David R.W.David, Kallenberg, Cees Gm, Lesavre, Philippe, Lockwood, Christopher Martin, Lüdemann, J., Mascart, Françoise, Mirapeix, Eduardo, Pusey, Charles Dickson, Rasmussen, Niels, Sinico, Renato A, Tzioufas, Athanasios, Wieslander, J., Wiik, Anna, van der Woude, Fokko J, Hagen, Ernst Christiaan, Andrassy, Konrad, Csernok, Elena, Daha, Mohamed, Gaskin, Gill, Gross, W.L., Hansen, Bettina, Heigl, Z., Hermans, Julie, Jayne, David R.W.David, Kallenberg, Cees Gm, Lesavre, Philippe, Lockwood, Christopher Martin, Lüdemann, J., Mascart, Françoise, Mirapeix, Eduardo, Pusey, Charles Dickson, Rasmussen, Niels, Sinico, Renato A, Tzioufas, Athanasios, Wieslander, J., Wiik, Anna, and van der Woude, Fokko J

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) are diagnostic markers for systemic vasculitis. They are classically I detected by an indirect immunofluorescence test using normal donor neutrophils as substrate. This assay lacks antigenic specificity and is not quantitative. The 'EC/BCR Project for ANCA Assay Standardization' is an international collaboration study with the aim to develop and standardize solid phase assays for ANCA detection. In this part of the study the isolation and characterization of proteinase-3 and myeloperoxidase, the two main target molecules for ANCA, and the development and standardization of ELISAs with these antigens are described. Six laboratories successfully isolated purified proteinase-3 preparations that could be used. Three of these preparations, together with one myeloperoxidase preparation, were subsequently used for ANCA testing by ELISA. The ELISA technique was standardized in two rounds of testing in the 14 participating laboratories. The coefficient of variation of these new assays decreased from values of approx. 50% in the first round to approx. 20% in the second round. We conclude that purified proteinase-3 and myeloperoxidase can be used in standardized ELISAs for ANCA detection. Whether such procedures offer advantages over the IIF test will be determined in a prospective clinical study., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
1996

86. Determination of Primary Amino Acid Sequence and Unique Three-Dimensional Structure of WGH1, a Monoclonal Human IgM Antibody with Anti-PR3 Specificity

Author

Davis, Jacquelyn A., primary, Peen, Elisabeth, additional, Williams, Ralph C., additional, Perkins, Shane, additional, Malone, Christine C., additional, McCormack, Wayne T., additional, Csernok, Elena, additional, Gross, W.L., additional, Kolaskar, A.S., additional, and Kulkarni-Kale, Urmila, additional

Published
1998
Full Text
View/download PDF

88. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA) A report on the second phase of an international cooperative study on the standardization of ANCA assays

Author

Hagen, E.C., primary, Andrassy, K., additional, Csernok, E., additional, Daha, M.R., additional, Gaskin, G., additional, Gross, W.L., additional, Hansen, B., additional, Heigl, Z., additional, Hermans, J., additional, Jayne, D., additional, Kallenberg, C.G.M., additional, Lesavre, Ph., additional, Lockwood, C.M., additional, Lüdemann, J., additional, Mascart-Lemone, F., additional, Mirapeix, E., additional, Pusey, C.D., additional, Rasmussen, N., additional, Sinico, R.A., additional, Tzioufas, A., additional, Wieslander, J., additional, Wiik, A., additional, and Van der Woude, F.J., additional

Published
1996
Full Text
View/download PDF

92. Allergic reactions to mesna

Author

Seidel, Angelika, primary, Andrassy, K., additional, Ritz, E., additional, Kässer, U., additional, Lemmel, E.-M., additional, Gross, W.L., additional, Mohr, J., additional, and Christophers, E., additional

Published
1991
Full Text
View/download PDF

94. Wegener’s granulomatosis: disease course, assessment of activity and extent and treatment.

Author

de Groot, K. and Gross, W.L.

Subjects
*VASCULITIS, *NECROSIS, *EPIDEMIOLOGY, *PATHOLOGY, *THERAPEUTICS
Abstract

Wegener’s granulomatosis (WG) belongs to the group of necrotizing primary systemic vasculitides of unknown etiology, that are associated with anti-neutrophil cytoplasmic antibodies. The pathological hallmark of WG is the coexistence of vasculitis and granuloma. Due to more sensitive diagnostic instruments, especially ANCA testing, the incidence of diagnosis of WG has risen in the past ten years. Although the precise pathophysiology is not understood yet, there is ample evidence that ANCA, which can lead to cytotoxic reactions in the vascular texture, play a major role, possibly promoted by a dysbalance in the anti-idiotypic network. The clinical disease course is typically two-phasic, beginning with a granulomatous inflammation of the upper respiratory tract, that usually is followed by a generalized vasculitic phase, that can range from mild organ dysfuntion to lifethreatening multi-organ failure. Consequently, diagnostic procedures, patients’ assessment and therapeutic regimens need to be individualized, adapted to stage and activity of the disease as well as standardized. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

97. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome

Author

Schnabel, A., Csernok, E., Gross, W.L., and Braun, J.

Abstract

Background To obtain insight into the mechanisms of tissue injury in lung disease due to Churg-Strauss syndrome (CSS), the bronchoalveolar lavage (BAL) cell profile and the levels in the BAL fluid of cell products released by activated eosinophils and neutrophils were assessed. Methods Thirteen patients with active progressive CSS (n = 7) or CSS in partial remission (n = 6) underwent clinical staging and bronchoalveolar lavage. The levels of eosinophil cationic protein (ECP), myeloperoxidase (MPO), and peroxidase activity in the BAL fluid were determined and the results were compared with those of 19 patients with pulmonary active Wegener's granulomatosis (WG) and nine control subjects. Results In patients with progressive CSS the BAL cell profile was dominated by eosinophils, neutrophil elevation being the exception. The eosinophilia was associated with high ECP levels (4.39 ng/ml and 0.40 ng/ml in the two CSS groups compared with unmeasurable values in the controls). Individual patients with highly active CSS also had raised MPO levels, comparable to the levels in the most active WG patients. Peroxidase activity in the BAL fluid was 1.26 U/ml and 0.10 U/ml in the two groups of patients with CSS and 0.20 U/ml in the controls. Pulmonary disease in patients with WG was characterised by an extensive increase in MPO (0.30 ng/ml versus 0.13 ng/ml in the controls) together with high peroxidase activity in the BAL fluid (4.37 U/ml), but only a small increase in ECP levels was seen. No correlation was found between the ECP and MPO levels in patients with CSS which suggests that eosinophil and neutrophil activation vary independently of each other. Conclusions These findings suggest that, in addition to eosinophil activation, neutrophil activation is an important feature in some patients with highly active CSS. The balance of neutrophil and eosinophil involvement appears to be variable and this may be one explanation for the individually variable treatment requirements of patients with CSS.

Published
1999

98. Human Endothelial Cells Express Proteinase 3, the Target Antigen of Anticytoplasmic Antibodies in Wegener's Granulomatosis

Author

Mayet, W.-J., Csernok, E., Szymkowiak, C., Gross, W.L., and Biischenfelde, K.-H.Meyer zum

Abstract

Autoantibodies directed against cytoplasmic antigens of neutrophils (ANCA), especially proteinase 3 (PR-3), have proved to be a useful clinical tool confirming the diagnosis or monitoring disease activity of Wegener's granulomatosis (WG). Although several concepts concerning the pathophysiologic potentials of ANCA have been discussed, only sparse data about ANCA-endothelium interactions have been available. In this study, we have investigated the expression of PR-3 in cytokine-treated human endothelial cells using purified anti-PR-3 antibodies of patients with WG, murine and human monoclonal anti—PR-3 antibodies as probes. We were able to show that tumor necrosis factor-α, interleukin-1a/β, and interferon-γ led to an increased PR-3 expression in the cytoplasm of endothelial cells by performing polymerase chain reaction analysis, Western blot, cyto—enzyme-linked immunosorbent assays, and confocal laser scanning microscopy. Moreover, PR-3 was also translocated into the cell membrane, becoming accessible to ANCA. Our data suggest a possible direct pathogenic effect of anti—PR-3 antibodies in WG and other vasculitides. Anti—PR-3 antibodies represent an important missing link in ANCA-endothelial interactions.

Published
1993
Full Text
View/download PDF

99. 4 Systemic necrotizing vasculitis

Author

Gross, W.L.

Abstract

The revival of interest in systemic necrotizing vasculitis was initiated by the discovery of its association with anti-neutrophil cytoplasmic antibodies (ANCA). The close association of certain ANCA subspecificities, for example, proteinase 3 (Pr3) and myeloperoxidase ANCA, with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome has led to their designation as 'ANCA-associated vasculitides'. This article describes the common and divergent clinical and immunological features of the members of this 'new' family of systemic necrotizing vasculitis, which continues to grow with the widespread use of ANCA testing. In addition, the 'standard' treatment for systemic necrotizing vasculitis (daily 'low dose' cyclophosphamide plus glucocorticosteroids or 'Fauci's scheme') is compared with new stage and activity adapted therapeutic regimens.

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results